ProShare Advisors
STML

ProShare Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

ProShare Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,778
Closed -$262K – 2066
2013
Q3 		$262K Buy
+5,778
New +$188K 0.01% 1995

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ProShare Advisors's STML Position: Q4 2013 in Review

ProShare Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2013, closing a stake of 5,778 shares — an estimated $262K sold.

ProShare Advisors first reported a position in STML in Q3 2013 and held it in 1 quarter. The position peaked at $262K in Q3 2013. 69 funds tracked by Wall St. Rank hold STML as of Q4 2013.

  • ProShare Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • ProShare Advisors sold 5,778 Stemline Therapeutics, Inc. shares in Q4 2013, an estimated $262K.
  • ProShare Advisors first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • ProShare Advisors's Stemline Therapeutics, Inc. position peaked at $262K in Q3 2013.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2013.

Based on ProShare Advisors's 13F filing for Q4 2013, filed 4 Feb 2014.